MorphoSys AG American Depositary Shares - MOR STOCK NEWS

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte announced a positive opinion from the CHMP recommending conditional marketing authorization for tafasitamab in combination with lenalidomide for treating eligible adults with relapsed or refractory DLBCL in the EU. This follows U.S. FDA approval in July 2020. The CHMP's opinion, based on the Phase 2 L-MIND study, indicates a new therapeutic option for 30-40% of patients with limited treatment choices. The European Commission will now review the recommendation, and if approved, tafasitamab will be marketed as Minjuvi in the EU.

Incyte and MorphoSys announced a positive opinion from the European Medicines Agency’s CHMP recommending conditional marketing authorization for tafasitamab combined with lenalidomide for adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who can't undergo autologous stem cell transplantation (ASCT). This follows the FDA's approval in July 2020. Tafasitamab represents a crucial treatment option for the 30-40% of DLBCL patients who face poor prognoses. The final decision by the European Commission is awaited, with expectations to commercialize tafasitamab as Minjuvi in the EU.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) has initiated a cash tender offer to acquire all outstanding shares of Constellation Pharmaceuticals, Inc. (CNST) for $34.00 per share. This offer, part of a merger agreement dated June 2, 2021, will expire on July 14, 2021, unless extended. The tender is contingent upon a minimum majority of shares being tendered and other customary conditions. Following the completion, which is expected in Q3 2021, MorphoSys aims to advance Constellation's product pipeline, including key products like pelabresib (CPI-0610).

MorphoSys US Inc. and Incyte announced new three-year follow-up data from the Phase 2 L-MIND study of tafasitamab in combination with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The study included 80 patients and showed an overall response rate (ORR) of 57.5% and a complete response (CR) rate of 40%. The median duration of response (DoR) was 43.9 months with median overall survival (OS) at 33.5 months.

Results were presented at the 2021 ASCO Annual Meeting and indicate potential long-term disease control for difficult-to-treat DLBCL patients.

MorphoSys AG (FSE:MOR, NASDAQ:MOR) announced its acquisition of Constellation Pharmaceuticals for $34.00 per share, totaling $1.7 billion. The deal has received unanimous board approval and is set to close in Q3 2021. Additionally, MorphoSys entered a strategic funding partnership with Royalty Pharma, featuring a $1.425 billion upfront payment and $350 million in Development Funding Bonds. This acquisition aims to accelerate MorphoSys' oncology pipeline, leveraging Constellation's promising therapeutics, pelabresib and CPI-0209, in mid- to late-stage trials.

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share, totaling $1.7 billion. The acquisition aims to enhance MorphoSys's position in hematology-oncology by integrating Constellation's promising product candidates, pelabresib and CPI-0209, which are in advanced clinical trials. Additionally, a strategic funding partnership with Royalty Pharma will provide $1.425 billion in upfront financing to support the acquisition and development of the combined pipeline. The transaction is expected to close in Q3 2021.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will have its CEO, Jean-Paul Kress, participate in a fireside chat at the UBS Global Healthcare Conference on May 25, 2021, at 7:00 a.m. Eastern Time. The live audio can be accessed from the company’s website, with a replay available afterward. MorphoSys is focused on innovative therapies for cancer and autoimmune diseases, boasting a successful track record with products like Monjuvi (accelerated approval by the FDA in July 2020) and Tremfya (first regulatory approval in 2017). More details are available at morphosys.com.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced its participation in the 2021 ASCO Annual Meeting from June 4-8, 2021, where it will present new data on tafazitamab (Monjuvi^(R)). This antibody is used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The presentation includes three-year follow-up data from the Phase 2 L-MIND study, showcasing the treatment's durability and overall survival benefits. Details will also be shared from the First-MIND study, emphasizing Monjuvi's potential as a foundational therapy for DLBCL.

MorphoSys and Incyte announced the first patient has been dosed in the pivotal Phase 3 frontMIND trial, evaluating the combination of tafasitamab and lenalidomide with the standard R-CHOP treatment for high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Approximately 880 patients are targeted for enrollment, aiming to improve progression-free survival as the primary endpoint. DLBCL affects around 30,000 patients annually in the U.S., with current treatments having limited efficacy in high-risk cases.